Permeation pathways in rectal absorption

Enhancement in Drug Delivery

Volumn , Issue , 2006, Pages 136-146

  Watanabe, Yoshiteru ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056974343     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (65)

1. De Boer, A.G., L.G.J. De Leede, and D.D. Breimer. 1984. Drug absorption by sublingual and rectal routes. Br J Anaesth 56:69.
2. Muranishi, S. 1984. Characteristics of drug absorption via the rectal route. Methods Find Exp Clin Pharmacol 6:763.
3. Van Hoogdalem, E.J., A.G. De Boer, and D.D. Breimer. 1991. Pharmacokinetics of rectal drug administration, Part I. General considereations and clinical applications of centrally acting drugs. Clin Pharmacokinet 21:11.
4. Song, Y., et al. 2004. Mucosal drug delivery: Membranes, methodologies, and applications. Crit Rev Ther Drug Carrier Syst 21:195.
5. Binder, H.J., and G.I. Sandle. 1987. Electrolyte absorption and secretion in mammalian colon. In Physiology of the gastrointestinal tract, 2nd ed., ed. L.R. Johnson, 1389. New York: Raven Press.
6. Netter, F.H. 1973. The Ciba collection of medical illustrations: digestive system: lower digestive tract, vol. 3, ed. E. Oppenheimer, 57. Summit: Ciba Pharmaceutical Co.
7. De Boer, A.G., et al. 1982. Rectal drug administration: Clinical pharmacokinetic consideration. Clin Pharmacokinet 7:285.
8. Müller, B.W., ed. 1986. Suppositorien. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH.
9. Kaji, Y., et al. 1985. Selective transfer of 1-hexylcarbamoyl-5-fluorouracil into lymphatics by combination of b-cyclodextrin polymer complexation and absorption promoter in the rat. Int J Pharm 24:79.
10. Yoshikawa, H., et al. 1985. Comparison of disappearance from blood and lymphatic delivery of human fibroblast interferon in rat by different administration route. J Pharmacobiodyn 8:206.
11. Van Hoogdalem, E.J., A.G. De Boer, and D.D. Breimer. 1989. Intestinal drug absorption enhancement:an overview. Pharmacol Ther 44:407.
12. Lee, V.H.L. 1991. Peptide and protein drug delivery. New York: Marcel Dekker.
13. De Leede, et al. 1984. Rectal and intravenous propranolol infusion to steady state kinetics and b-receptor blockade. Clin Pharamcol Ther 35:148.
14. Jay, M., et al. 1985. Disposition of radiolabelled suppositories in humans. J Pharm Pharmacol 37:266.
15. Hardy, J.G., et al. 1987. The application of gamma-scintigraphy for the evaluation of the relative spreading of suppository bases in rectal hard gelatin capsules. Int J Pharm 38:103.
16. Sugito, K., et al. 1988. The spreading of radiolabelled fatty suppository bases in human rectum. Int J Pharm 47:157.
17. Vitti, R.A., et al. 1989. Quantitative distribution of radiolabelled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis. Dig Dis Sci 34:1792.
18. Van Buul, M.M., et al. 1989. Retrograde spread of therapeutic enemas in patients with inflammatory bowel disease. Hepatogastroenterology 36:199.
19. Dupont, C., and M. Heyman. 2000. Food protein-induced enterocolitis syndrome: Laboratory perspectives. J Pediatr Gastroenterol Nutr Suppl. no. 30:S57.
20. Thorn, M., et al. 2000. Intestinal mucosal secretion of basic fibroblast growth factor in patients with ulcerative colitis. Scand J Gastroenterol 35:501.
21. Taha, Y., et al. 2001. Evidence of local eosinophil activation and altered mucosal permeability in collagenous colitis. Dig Dis Sci 46:888.
22. Taha, Y., et al. 2004. Vascular endothelial growth factor (VEGF)-a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci 49:109.
23. Koga, K., et al. 2004. Membrane permeability and antipyrine absorption in a rat model of ischemic colitis. Int J Pharm 286:41.
24. Linskens, R.K., et al. 2001. The bacterial flora in inflammatory bowel disease: Current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. no. 234:29.
25. O’Connor T.M., et al. 2004. The role of substance P in inflammatory disease. J Cell Physiol 201:167.
26. Nejdfors, P., et al. 2000. Intestinal permeability in humans is increased after radiation therapy. Dis Colon Rectum 43:1582.
27. Kierbel, A., et al. 2000. Effects of medium hypertonicity on water permeability in the mammalian rectum: Ultrastructural and molecular correlates. Pflugers Arch 440:609.
28. Lugea, A., et al. 2000. Surface hydrophobicity of the rat colonic mucosa is a defensive barrier against macromolecules and toxins. Gut 46:515.
29. De Leede, L.G.J., et al. 1982. Zero-order rectal delivery of theophylline in man with an osmotic system, J Pharmacokinet Biopharm 10:525.
30. De Leede, L.G.J., et al. 1986. Rate-controlled rectal delivery in man with a hydrogel preparation. J Control Rel 4:17.
31. Breimer, D.D., et al. 1985. Rate controlled rectal drug delivery. In Rate control in drug therapy, eds. L.F. Prescott, and W.S. Nimmo, 54. Edinburgh: Churchill Livingstone.
32. Hanning, C.D., et al. 1988. The morphine hydrogel suppository. Br J Anaesth 61:221.
33. De Leede, L.G.J., et al. 1984. Site specific rectal drug administration in man with an osmotic system:Influence on “first-pass” elimination of lidocaine. Pharm Res 1:129.
34. Van Hoogdalem, E.J., et al. 1989. Rate-controlled rectal absorption enhancement of cefoxitin by coadministeration of sodium salicylate or sodium octanoate in healthy volunteers. Br J Clin Pharmacol 27:75.
35. Nishimura, K., et al. 1985. Studies on the promoting effects of carboxylic acid derivatives on the rectal absorption of b-lactam antibiotics in rats. Chem Pharm Bull 33:282.
36. Bergogne-Bérézin, E., and A. Bryskier. 1999. The suppository form of antibiotic administration:Pharmacokinetics and clinical application. J Antimicrob Chemother 43:177.
37. Lindmark, T., et al. 1997. Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Phram Res 14:930.
38. Lindmark, T., T. Nikkilä, and P. Artursson. 1995. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 275:958.
39. Van Hoogdalem, E.J., et al. 1988. Absorption enhancement of rectally infused cefoxitin sodium by medium-chain fatty acids in conscious rats: Concentration-effect relationship. Pharm Res 5:453.
40. Watanabe, Y., et al. 1994. Bioavailability of gentamicin from a new rectal dosage vehicle in rabbtis. Yakuzaigaku 54:122.
41. Takahashi, H., et al. 1997. The enhancing mechanism of capric acid (C10) from a suppository on rectal drug absorption through a paracellular pathway. Biol Pharm Bull 20:446.
42. Lennernas, H., et al. 2002. The influence of caprate on rectal absorption of phenoxymethylpenicillin:Experience from an in-vivo perfusion in humans. J Pharm Pharmacol 54:499.
43. Watanabe, Y., et al. 1988. Absorption enhancement of rectally infused cefoxitin by medium chain monoglycerides in conscious rats. J Pharm Sci 77:847.
44. Van Hoogdalem, E.J., et al. 1989. Rectal absorption enhancement of des-enkephalin-g-endorphin (DegE) by medium-chain glycerides and EDTA in conscious rats. Pharm Res 6:91.
45. Van Hoogdalem, E.J., et al. 1990. Absorption enhancement of rectally infused insulin by sodium tauro-24,25-dihydrofusidate (STDHF) in rats. Pharm Res 7:180.
46. Watanabe, Y., et al. 1992. Absorption enhancement of polypeptide drugs by cyclodextrins. I. Enhanced rectal absorption of insulin from hollow-type suppositories containing insulin and cyclodextrins in rabbits. Chem Pharm Bull 40:3042.
47. Matsuda, H., and Arima, H. 1999. Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliv Rev 36:81.
48. Utoguchi, N., et al. 1998. Nitric oxide donors enhance rectal absorption of macromolecules in rabbits. Pharm Res 15:870.
49. Murakami, T., et al. 2000. Enhancing effect of 5 a-cyprinol sulfate on mucosal membrane permeability to sodium ampicillin in rats. Eur J Pharm Biopharm 49:111.
50. Koga, K., et al. 2003. Preparation and rectal absorption of highly concentrated glycyrrhizin solution. Biol Pharm Bull 26:1299.
51. Sayani, A.P., I.K. Chun, and Y.W. Chien. 1993. Transmucosal delivery of leucine enkephalin:Stabilization in rabbits enzyme extracts and enhancement of permeation through mucosae. J Pharm Sci 82:1179.
52. De Boer, A.G., E.J. Van Hoogdalem, and D.D. Breimer. 1992. (D) Routes of delivery: Case studies, (4) rate-controlled rectal peptide drug absorption enhancement. Adv Drug Deliv Rev 8:237.
53. Nishihata, T., et al. 1989. Effectiveness of insulin suppositories in diabetic patients. J Pharm Pharmacol 4:799.
54. Onuki, Y., et al. 2000. In vivo effects of highly purified docosahexaenoic acid on rectal insulin absorption. Int J Pharm 198:147.
55. Uchida, T., et al. 2001. Preparation and characterization of insulin-loaded acrylic hydrogels containing absorption enhancers. Chem Pharm Bull 49:1261.
56. Watanabe, Y., et al. 1996. Pharmacokinetics and pharmacodynamics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after administration of a rectal dosage vehicle. Biol Pharm Bull 19:1059.
57. Watanabe, Y., et al. 1998. Studies of drug delivery systems for a therapeutic agent used in osteoporosis. I. Pharmacodynamics (hypocalcemic effect) of elcatonin in rabbits following rectal administration of hollow-type suppositories containing elcatonin. Biol Pharm Bull 21:1187.
58. Kowari, K., et al. 2002. Pharmacokinetics and pharmacodynamics of human chorionic gonadotropin (hCG) after rectal administration of hollow-type suppositories containing hCG. Biol Pharm Bull 25:678.
59. Watanabe, Y., et al. 1986. Pharamaceutical evaluation of hollow type suppositories. IV. Improvement of bioavailability of propranolol in rabbits after rectal administration. J Pharmacobiodyn 9:526.
60. Liu, Y., et al. 2005. Pharmacodynamics and pharmacokinetics of recombinant hirudin via four nonparenteral routes. Peptides 26:243.
61. Van Hoogdalem, E.J., et al. 1990. Topical effects of absorption enhancing agents on the rectal mucosa of rats in vivo. J Pharm Sci 79:866.
62. Swenson, E.S., W.B. Milisen, and W. Curatolo. 1994. Intestinal permeability enhancement efficacy, acute local toxicity, and reversibility. Pharm Res 11:1132.
63. Numata, N., et al. 2000. Improvement of intestinal absorption of macromoleclules by nitric oxide donor. J Pharm Sci 89:1296.
64. Watanabe, Y., et al. 2000. Absorption enhancement of a protein drug by nitric oxide donor: Effect on nasal absorption of human granulocyte colony-stimulating factor. J Drug Target 8:185.
65. Miyake, M., et al. 2004. Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorpbable drug, by utilizing sodium laurate and taurine. J Control Rel 99:63.